Navigation Links
Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol

Researchers at The University of Texas M. D. Anderson Cancer Center have developed a way to test whether the new targeted therapy Tarceva and the widely used chemotherapy drug Taxol are effectively killing tumor cells. They say that with further refinement, the test may make it possible to accurately assess whether patients are responding to these agents, as well as potentially others, within days of beginning therapy.

In two different studies being presented at the annual meeting of the American Association for Cancer Research (AACR), the research team will describe how the test measures the activity of several members of the cyclin-dependent kinase (CDK) family of enzymes, which are the triggering molecules that allow a cell to grow and divide. CDK cell cycle enzymes are the end target of numerous cellular pathways that are involved in cancer development and progression, the researchers say.

Before these studies, no one has been able to accurately test the function of enzymes from a tumor sample, says Naoto Ueno, M.D., Ph.D., an associate professor in the Breast Cancer Translational Research Laboratory and the Department of Blood and Marrow Transplantation.

"Testing CDK only has been possible by measuring gene expression, but our industry collaborator has provided a way that lets us test real enzyme activity within a human tumor sample," he says. "Our hope is to be able to use this system as a molecular marker to assess whether an anti-cancer therapy is working."

ABSTRACT # 1670

Sensitivity to Tarceva Depends on CDK2

In the first study, M. D. Anderson researchers found that loss of the CDK2 enzyme strongly correlated with a cancer's sensitivity to Tarceva.

That means testing activity of CDK2, the enzyme that drives cell division, can reveal whether or not a tumor will respond to Tarceva, says Naoto Ueno, M.D., Ph.D., an associate professor in the Breast Cancer Translational Research Laboratory and the Departm
'"/>

Source:University Of Texas M. D. Anderson Cancer Center


Page: 1 2 3

Related biology news :

1. Measuring the impact of post-genomics on Mediterranean populations
2. Measuring hormone cuts antibiotic use in half in pneumonia patients
3. Measuring hidden parasites in falciparum malaria
4. Measuring artery repair cells could become new heart disease test
5. Adding Radiation Therapy To Chemotherapy Improves Survival In Patients With High-risk Breast Cancer
6. Jump-starting T Cells In Skin Cancer
7. Deficient DNA Repair Capacity Associated With Increased Risk Of Breast Cancer
8. Fox Chase Cancer Center scientists identify immune-system mutation
9. Breakthrough Microarray-based Technology for the Study of Cancer
10. Yale Scientists Find MicroRNA Regulates Ras Cancer Gene
11. Fundamental Finding Yields Insight into Stem Cells, Cancer; Opens Door to Drug Discovery
Post Your Comments:
(Date:8/5/2015)... August 5, 2015 According to ... Management Market by Software, Services, Vertical (BFSI, Airport, IT & ... - Global Forecast to 2020", published by MarketsandMarkets, defines ... globally into various segments. The global PIAM Market is ... $546.2 Million by 2019, at a CAGR of 14.9 ...
(Date:8/4/2015)... Aug. 04, 2015 ... has announced the addition of the ... and Service), Sub-Segment (Computer Forensics, Network Forensics, ... Types, Service, Vertical and Region - Global ... offering. By Component (Hardware, Software, ...
(Date:7/31/2015)... Kina, 31. juli 2015 Den 10. internationale ... af BGI fra den 22. - 25. oktober i ... fejrer sin 10-års fødselsdag i år. Siden starten i ... årlige møder på ,omik,-feltet, og er en af de ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... known that racing cars and bicyclists can reduce air ... from New York University and Cornell University have found ... flags. Their study, published in the most recent issue ... that in a series of flags, the leading flag ...
... increasing popularity of reduced tillage on crops has not ... but it has also been associated with increasing organic ... peanut crops, however, reduced tillage has not gained a ... inconsistent yields have not encouraged farmers to make a ...
... With childhood obesity increasing, school administrators and public health ... schools. In a study published in the November/December 2008 ... Behavior , researchers found that reduction or elimination of ... consumption by adolescents. Working with four schools ...
Cached Biology News:Lead-flapping objects experience less wind resistance than their trailing counterparts 2Tillage, rotation impacts peanut crops 2
(Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage Biotech ... PBT.U), and Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... Phase I study of BHV-0223, a glutamate modulating ... regarding BHV-0223 and recently obtained clearance from the ... with human testing. Portage holds 54% equity interest ...
(Date:8/27/2015)... , August 27, 2015 GlassesOff ... image processing functions in the human vision system, announced today ... point guard Chris Paul to develop a ... who want to improve their real-life on-court performance. ... court, whether it is shooting a ball or blocking a ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
Breaking Biology Technology:Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3
... Recurring Disposables, Services and Accessories Revenue ... Irrigated Catheter Launch Provided, ST. LOUIS, March 3 ... the fourth quarter and full year,ended December 31, 2007., ... to $39.3 million,compared with $27.2 million in 2006. Sales ...
... Feb. 29 For the first time,researchers at ... spheres whose halves are physically or chemically,different -- ... when an alternating electrical field is applied to ... research, published in the Feb. 8, 2008, edition,of ...
... Feb. 29 Kendle (Nasdaq: KNDL ... today,announced that Vice President and Chief Marketing ... Annual Raymond James,Institutional Investors Conference. The conference ... Cypress in Orlando, March 2-5, 2008. Kendle,s,presentation ...
Cached Biology Technology:Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 2Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 3Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 4Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 5Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 6Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 7Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 8Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 9Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results 10'Two-Faced' Particles Act Like Tiny Submarines 2'Two-Faced' Particles Act Like Tiny Submarines 3Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference 2
... LiCl precipitation offers major advantages over other ... precipitate DNA, protein or carbohydrates. It is the ... or cDNA synthesis from RNA preparations. Note, LiCl ... total RNA isolations. If the RNA is to ...
...
...
The Captivate Disposable Sample Chamber is designed for use with the Captivate magnetic yoke assembly (C-24700) and can be used with our Captivate ferrofluid conjugates (C-21473 C-21474 C-21476) or ...
Biology Products: